From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
Recruiting · NCT04873492 · Interventional (participants receive a specific treatment) · Lead sponsor: Nantes University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls
Who can take part
Inclusion criteria
- Common criteria for retrospective MS patients:
- Patients aged 18 years or older
- Clinical isolated syndrome (CIS) with or without dissemination in space
- Patients affiliated to an appropriate health insurance
- Criteria for Aggressive MS group
- Start of a 2nd line therapy within the two years following the CIS
- Criteria for Non aggressive MS group
- No conversion according to McDonald criteria from clinical isolated syndrome to multiple sclerosis within 2 years or
- Conversion based to McDonald criteria treated or not with first line disease modifying therapy within 2 years.
- Have a minimum of least 2 years of follow-up.
- Healthy volunteers
- Aged 18 years or older
- No history of clinically isolated syndrome or MS
- Pairing criteria :
- Age +/- 5 years
- Sex
- Prospective MS Patients
- Patients aged 18 years or older
- Clinical isolated syndrome (CIS) with or without dissemination in space
- Patients affiliated to an appropriate health insurance
Exclusion criteria
- Ongoing participation to a another study
- Refusal to genetic analyses
- Immunosuppressive drug at the time of blood collection
- Plasma exchange or corticosteroid treatment within the four weeks prior to blood sample
- Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard)
- Pregnancy
Where it is running
1 location listed.
- Nantes University Hospital - Nantes, Loire-Atlantique, France